Comparison of immunosuppressive therapeutic regimens in patients with nephrotic syndrome due to idiopathic membranous nephropathy

Renal Failure

Volumn 32, Issue 5, 2010, Pages 566-571

  Kosmadakis, George ^a   Filiopoulos, Vasileios ^a   Smirloglou, Despoina ^a   Skarlas, Panayotis ^a   Georgoulias, Christodoulos ^a   Michail, Spiridon ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

ACE inhibitor; Cyclophosphamide; Cyclosporine; Idiopathic membranous nephropathy; Nephrotic syndrome

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; LISINOPRIL; METHYLPREDNISOLONE;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HERPES ZOSTER; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IDIOPATHIC DISEASE; KIDNEY FUNCTION; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; SODIUM INTAKE; TREATMENT RESPONSE;

CYCLOPHOSPHAMIDE; CYCLOSPORINE; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LISINOPRIL; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; PROSPECTIVE STUDIES;

EID: 77952974800     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860221003728754     Document Type: Article

References (16)

1. Mason PD, Pusey CD. Glomerulonephritis: Diagnosis and treatment. BMJ. 1994;309(6968):1557-1563.
2. Honkanen E, Törnroth T, Grönhagen-Riska C. Natural history, clinical course and morphological evolution of membranous nephropathy. Nephrol Dial Transplant. 1992;(Suppl. 1):35-41.
3. Ponticelli C, Passerini P. Membranous nephropathy. In: Ponticelli C, Glassock RJ, eds. Treatment of Primary Glomerulonephritis. Oxford: Oxford University Press; 1997:146-185.
4. Passerini P, Pasquali S, Cesana B, Zucchelli P, Ponticelli C. Long-term outcome of patients with membranous nephropathy after complete remission of proteinuria. Nephrol Dial Transplant. 1989;4:525-529.
5. Quaglia M, Stratta P. Idiopathic membranous nephropathy: Management strategies. Drugs. 2009;69(10):1303-1317.
6. Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis. 1995;25:862-875.
7. Imperiale TF, Goldfarb S, Berns JS. Are cytotoxic agents beneficial in idiopathic membranous nephropathy? A meta-analysis of the controlled trials. J Am Soc Nephrol. 1995;5:1553-1558.
8. Fujimoto S, Hara S, Sato Y, Yamada K, Hisanaga S, Eto T. Nephrotic syndrome caused by membranous nephropathy: Response to a short course of cyclophosphamide alternating with prednisolone. Intern Med. 2004;43(1):30-34.
9. Goumenos DS, Kalliakmani P, Tsakas S, Sotsiou F, Vlachojannis JG. The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy. Clin Nephrol. 2004;61(1):17-24.
10. Branten AJ, Reichert LJ, Koene RA, Wetzels JF. Oral cyclo-phosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. QJM. 1998;91(5):359-366.
11. Schieppati A, Perna A, Zamora J, Giuliano GA, Braun N, Remuzzi G. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2004;18(4):CD004293.
12. Praga M, Hernández E, Montoyo C, Andrés A, Ruilope LM, Rodicio JL. Long-term beneficial effects of angiotensinconverting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis. 1992;20(3):240-248.
13. Tylicki L, Rutkowski P, Renke M, et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: An open-label crossover randomized controlled trial. Am J Kidney Dis. 2008;52(3):486-493.
14. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349(9069):1857-1863.
15. Ruggenenti P, Mosconi L, Vendramin G, et al. ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome. Am J Kidney Dis. 2000;35:381-391.
16. Gansevoort RT, Heeg JE, Vriesendorp R, de Zeeuw D, de Jong PE. Antiproteinuric drugs in patients with idiopathic membranous glomerulopathy. Nephrol Dial Transplant. 1992;7(Suppl. 1):91-96.